New Cancer Trials Show Improved Survival with Novel Therapies
Recent clinical trials report significant progression-free survival gains for new antibody-drug conjugates and immunotherapies across multiple cancer types.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
2 publishers have covered this in 8 articles since 24 Oct 2026. MedPageToday.com - medical news for physicians published first, on 24 October at 21:02 UTC; Scientific Reports followed 122h 58m later. The most recent article, from Scientific Reports, appeared on 30 October at 00:00 UTC.
Outlets reporting it: Scientific Reports (major outlet), MedPageToday.com - medical news for physicians.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- MedPageToday.com - medical news for physiciansNovel ADC Achieves Impressive PFS Advantage in HER2-Low Metastatic Breast Cancer
- MedPageToday.com - medical news for physiciansNovel Drug Doubles PFS in Heavily Pretreated, HR-Positive Breast Cancer
- MedPageToday.com - medical news for physiciansTrial Results Show 'Something We Have Not Seen for Years' in Osteosarcoma
- MedPageToday.com - medical news for physiciansNovel HDAC Inhibitor Hits Main Goal in Unresectable Melanoma Trial
- MedPageToday.com - medical news for physiciansAnother Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer
- MedPageToday.com - medical news for physiciansChemo-Free First-Line Treatment Yields Huge PFS Gain in dMMR Endometrial Cancer
- MedPageToday.com - medical news for physiciansIntensified Adjuvant Chemo No Better Than Standard in High-Risk Colon Cancer
- Scientific ReportsTargeting M2 Macrophages Enhances the Efficacy of PD-L1 Blockade in Non-small Cell Lung Cancer
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Targeting M2 Macrophages Enhances the Efficacy of PD-L1 Blockade in Non-small Cell Lung Cancer Scientific Reports ·
- Intensified Adjuvant Chemo No Better Than Standard in High-Risk Colon Cancer MedPageToday.com - medical news for physicians
- Chemo-Free First-Line Treatment Yields Huge PFS Gain in dMMR Endometrial Cancer MedPageToday.com - medical news for physicians
- Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer MedPageToday.com - medical news for physicians
- Novel HDAC Inhibitor Hits Main Goal in Unresectable Melanoma Trial MedPageToday.com - medical news for physicians
- Trial Results Show 'Something We Have Not Seen for Years' in Osteosarcoma MedPageToday.com - medical news for physicians
- Novel Drug Doubles PFS in Heavily Pretreated, HR-Positive Breast Cancer MedPageToday.com - medical news for physicians
- Novel ADC Achieves Impressive PFS Advantage in HER2-Low Metastatic Breast Cancer MedPageToday.com - medical news for physicians